Embera NeuroTherapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

BOSTON, Mass. and SHREVEPORT, La. – August 31, 2017 – Embera NeuroTherapeutics, Inc.,
a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other
addictions, today announced that Robert (Bob) Linke, the Company’s President and Chief
Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will
provide a corporate update at the 19th Annual Rodman & Renshaw Global Investment
Conference. The presentation will be on Monday, September 11, 2017 at 9:35 a.m. Eastern time.
The conference is being held from September 10-12, 2017 at Lotte New York Palace Hotel in
New York, New York.

About Embera NeuroTherapeutics

Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating
a broad range of addictions where the major clinical challenge is a limited range of effective
therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain
functions related to stress responses that drive craving and relapse associated with these
disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and
smoking cessation. www.emberaneuro.com


Bob Linke President and CEO
Embera NeuroTherapeutics, Inc.
[email protected]

For Media:
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, 781-235-3060
[email protected] or [email protected]